心脏毒性
曲妥珠单抗
医学
心脏功能不全
神经调节蛋白
生物信息学
药理学
内科学
毒性
心力衰竭
生物
乳腺癌
癌症
受体
作者
G. Milano,Emilie Serres,Jean-Marc Ferrero,Joseph Ciccolini
出处
期刊:Current Drug Targets
[Bentham Science]
日期:2014-12-04
卷期号:15 (13): 1200-1204
被引量:7
标识
DOI:10.2174/1389450115666141114151911
摘要
Optimal identification of the risk of developing cardiotoxicity upon trastuzumab (TZM) treatment appears necessary as this risk may impair treatment compliance and compromise long-term recovery. To better understand and predict cardiac toxicity, the molecular mechanisms underlying this phenomenon need to be known. HER2 is present at the cell surface of cardiomyocytes. Neuregulin is produced by cardiac endothelial cells and binds to HER4, thus leading to dimerization with HER2 and subsequent cell signaling necessary for normal cardiac function. Decreasing HER2 activity has a major impact on cardiomyocyte function. However, the precise molecular mechanisms responsible for TZM-induced cardiac dysfunction are still unclear. This mini-review aims to summarize genetic, pharmacological and medical data helping to identify mechanisms that could explain cardiotoxicity. Of potential interest, these mechanisms highlight the importance of HER2 genetic polymorphism (Val655Ile) in the identification of patients at risk of developing TZMinduced cardiac effects. Keywords: Cardiotoxicity, genetic polymorphism, HER2, personalized treatment, trastuzumab.
科研通智能强力驱动
Strongly Powered by AbleSci AI